Jaisim Shah

Protein Design Labs, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a company of development of humanized antibodies, It has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products.

Azelon Pharmaceuticals, Inc. develops biopharmaceutical drugs for the treatment of osteoporosis. It develops parathyroid hormone analogs for the treatment of bone diseases, which are characterized by deficits in bone formation, including osteoporosis, orthopedic conditions and renal bone disease. The company was founded by Paul Morley and Godfrey Marchand in 2000 and is headquartered in West Conshohocken, PA.

Pulmatrix Operating Co., Inc. develops pharmaceutical products for respiratory infectious diseases. Its iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov and Robert S. Langer in 2003 and is headquartered in Lexington, MA.

Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA.

Semnur Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. The firm focuses on the clinical and commercial development of products such as SP-102: a non-opioid epidural steroid injectable potentially for the treatment of Lumbosacral radicular pain. The company was founded by Mahendra G. Shah in 2013 and is headquartered in Mountain View, CA.

SCILEX Pharmaceuticals, Inc. engages in the development and commercialization of pharmaceutical products. It acquires late-stage clinical development and sales and marketing of generic and branded generic products. Its product includes ZTlido. The company was founded by Anthony P. Mack and William Pedranti in 2011 and is headquartered in Berwyn, PA.